As of early 2026, the clinical research landscape for entheogenic and psychedelic compounds has reached a critical juncture. Multiple Phase III trials have completed or are nearing completion, FDA advisory committees have weighed in, and the question has shifted from “do these substances work?” to “how do we regulate their use?”

This overview documents the current state of clinical research for journalists, scholars, and policy researchers.

MDMA-Assisted Therapy for PTSD

Sponsor: Lykos Therapeutics (formerly MAPS Public Benefit Corporation)

Status: In 2024, the FDA advisory committee voted against approving Lykos’s New Drug Application for MDMA-assisted therapy, citing concerns about trial methodology (particularly around blinding, given MDMA’s obvious subjective effects) and safety monitoring. The FDA subsequently declined to approve the application in its current form, requesting additional data.

What this means: MDMA-assisted therapy showed strong efficacy signals — 71% of participants in Phase III no longer met PTSD diagnostic criteria vs. 48% in the placebo group. The rejection was not about efficacy but about regulatory methodology. Lykos is expected to submit revised data.

Key question for journalists: The FDA’s concerns about blinding in psychedelic trials raise a fundamental methodological challenge — how do you run a double-blind trial for a substance whose effects are unmistakable to the participant? This question affects all psychedelic clinical trials, not just MDMA.

Psilocybin for Treatment-Resistant Depression

Sponsors: COMPASS Pathways (Phase IIb/III), Usona Institute (Phase II)

Status: COMPASS Pathways’ COMP360 psilocybin therapy received FDA Breakthrough Therapy designation in 2018. Phase IIb results showed statistically significant improvement in depression scores at the highest dose (25mg). Phase III trials are ongoing.

Usona Institute’s psilocybin investigation for Major Depressive Disorder (MDD) also received Breakthrough Therapy designation.

Key data points:

  • Single-dose 25mg psilocybin produced rapid, sustained antidepressant effects lasting weeks to months
  • Response rates significantly exceeded those of conventional antidepressants in treatment-resistant populations
  • Most common adverse events: headache, nausea, emotional distress (generally transient)

Psilocybin for Other Conditions

Active clinical research programs also target:

  • Alcohol use disorder (NYU, multiple sites)
  • Tobacco cessation (Johns Hopkins — pilot data showed 80% abstinence at 6 months)
  • Anorexia nervosa (Johns Hopkins, Imperial College London)
  • OCD (Yale, multiple sites)
  • Cluster headaches (multiple academic sites — strong anecdotal evidence, limited formal trials)
  • End-of-life anxiety (NYU, Johns Hopkins — Phase II data showed dramatic reductions in anxiety and depression in terminal cancer patients)

Other Compounds Under Investigation

Compound Condition Stage Notable Institutions
LSD Anxiety, depression Phase II MindMed, University Hospital Basel
DMT Depression Phase I/II Small Pharma (now acquired by Cybin)
Ibogaine Opioid use disorder Phase I/II MAPS, DemeRx
5-MeO-DMT Treatment-resistant depression Phase I GH Research
Ketamine (IV/nasal) Depression Approved (esketamine) Johnson & Johnson (Spravato)
Mescaline Various Preclinical Limited formal research

The Structural Challenges

1. The Therapy Model Problem

Most psychedelic clinical trials use a “drug + therapy” model: patients receive the substance in a controlled setting with trained therapists present before, during, and after. This creates a regulatory challenge — the FDA approves drugs, not therapy protocols. How do you separate the molecule from the context?

2. The Patent Problem

Pharmaceutical development depends on patent protection to justify R&D investment. Natural compounds (psilocybin, mescaline, DMT) cannot be patented in their natural form. This has driven companies toward novel formulations, synthetic analogs, and proprietary delivery mechanisms — which may not serve patients better than the natural compounds.

3. The Access Problem

Clinical trial settings require trained therapists, controlled environments, and hours-long sessions. At scale, this model is extremely expensive. If psilocybin-assisted therapy costs $5,000-$10,000 per session, who has access?

4. The Integration Problem

Clinical trials measure outcomes at fixed intervals (2 weeks, 4 weeks, 6 months). But practitioners report that integration — the process of incorporating insights from the experience into daily life — is the critical factor in long-term outcomes. Integration support is not standardized, not well-studied, and not part of the pharmaceutical approval framework.

What to Watch in 2026

  1. Lykos/MAPS resubmission — If revised MDMA data satisfies FDA concerns, approval could come this year, making MDMA the first classical psychedelic approved as a medicine in the US.

  2. COMPASS Pathways Phase III results — If positive, psilocybin could be on a path to FDA approval by 2027-2028.

  3. State-level access programs — Oregon’s psilocybin service centers are operational. Colorado’s are being established. These create access outside the pharmaceutical framework.

  4. Insurance coverage decisions — Even if approved, will insurance cover psychedelic-assisted therapy? The cost structure will determine who benefits.

  5. International developments — Australia became the first country to allow prescription of MDMA and psilocybin (July 2023). Canada has expanded Special Access Program use. The global landscape is shifting.

Sources include published clinical trial results, ClinicalTrials.gov registry data, FDA public meeting transcripts, and peer-reviewed literature. Entheo.News is a documentation archive for journalists, scholars, and legal researchers.